A passionate advocate for Indian patients, Sanjiv Navangul, managing director of Janssen India, discusses the company’s public health work in the field of tuberculosis (TB) and multi-drug resistant TB (MDR-TB) in support of the Government of India’s efforts to end TB, including providing access to novel drug bedaquiline, initiating a research partnership with the Council of Scientific and Industrial Research (CSIR) and forging multiple partnerships with NGOs and State governments. He also explains how Janssen ensures it remains patient-centric and offers views on the importance of patient-centricity.
Mr. Navangul, you have been managing Janssen India for four years and four months. The company can be defined as a transformational medical innovator – as such what is the role of Janssen in India?
"Besides doctors and patients, our own employees are also incredibly important."
